Biotherapy, Immunotherapy, and Immune-Related Adverse Events
Key Takeaways
- Biotherapy and immunotherapy alter immune signaling or immune recognition, so toxicities may look different from classic chemotherapy toxicity.
- Checkpoint inhibitors can cause immune-related adverse events in nearly any organ system, sometimes weeks to months after treatment starts or after treatment ends.
- Early recognition of pneumonitis, colitis, hepatitis, endocrinopathy, nephritis, myocarditis, neurologic toxicity, and severe skin reactions is an RN priority.
- Patient education must stress reporting new symptoms before self-treating with over-the-counter drugs, antidiarrheals, or steroids unless instructed.
- Escalation depends on severity, affected organ, vital sign instability, and protocol guidance; nurses should not independently grade, hold, or restart therapy outside policy.
Biotherapy, Immunotherapy, and Immune-Related Adverse Events
Biotherapy is a broad term for treatments that use living systems, immune mediators, monoclonal antibodies, vaccines, cytokines, or engineered immune approaches to treat cancer. Immunotherapy is a major part of this group and includes immune checkpoint inhibitors, cytokine-based therapy, monoclonal antibodies with immune effects, cellular therapies, and combinations with chemotherapy or targeted agents. These treatments may not cause the same degree of alopecia or marrow suppression as many cytotoxic drugs, but they can cause inflammatory, immune, allergic, or cytokine-driven emergencies.
How Checkpoint Inhibitors Work
Checkpoint inhibitors block inhibitory signals such as PD-1, PD-L1, or CTLA-4 pathways, helping T cells recognize and attack cancer cells. The same mechanism can reduce immune tolerance in normal tissue. Immune-related adverse events, often called irAEs, can affect the skin, bowel, liver, lungs, kidneys, endocrine glands, heart, nervous system, eyes, joints, or blood cells. Timing is variable: rash and diarrhea may occur early, endocrine problems may evolve gradually, and toxicities can appear after treatment is held or completed.
| Organ system | Symptoms to assess |
|---|---|
| Lung | New cough, shortness of breath, chest tightness, oxygen need |
| Bowel | Diarrhea, abdominal pain, blood or mucus in stool, dehydration |
| Liver | Jaundice, dark urine, right upper quadrant pain, abnormal liver tests |
| Endocrine | Severe fatigue, headache, dizziness, hypotension, heat or cold intolerance, glucose change |
| Skin | Diffuse rash, blistering, mucosal sores, painful skin, fever |
RN Assessment Priorities
The nurse should ask targeted questions at every visit because patients may minimize symptoms when they feel hopeful about a new therapy. Compare bowel pattern with baseline, review respiratory status, ask about headache and vision changes, assess fatigue severity, and check for new muscle weakness, chest pain, palpitations, confusion, or decreased urine output. Laboratory monitoring commonly includes liver tests, kidney function, blood counts, thyroid tests, glucose, and other tests ordered by the oncology team. The RN should recognize trends and report clinically important changes rather than waiting for severe symptoms.
Patient Education
Patients need to understand that immune toxicity is not an allergy in the usual sense and is not always limited to infusion day. Teach them to call for persistent diarrhea, new shortness of breath, worsening cough, yellow skin or eyes, severe headache, confusion, fainting, new weakness, chest pain, palpitations, severe rash, eye pain, or inability to keep fluids down. They should avoid self-treating significant diarrhea or respiratory symptoms without calling the oncology team because masking symptoms can delay evaluation. Wallet cards or treatment cards help emergency clinicians identify the therapy.
Management Boundaries
Management of irAEs may involve holding therapy, corticosteroids, endocrine replacement, specialty consultation, imaging, stool studies, infectious workup, or hospital care. The RN supports triage, symptom grading under institutional tools, patient communication, and care coordination, but does not independently prescribe steroids or restart immunotherapy after toxicity. Because infection, disease progression, pulmonary embolism, medication effects, and immune toxicity can overlap, prompt provider involvement is essential.
Infusion and Cytokine Risks
Some biologic agents can cause acute infusion reactions, cytokine release, fever, chills, hypotension, hypoxia, or rigors. Monitoring should match the agent's risk profile and institutional policy, including extended observation when required. Escalate rapidly for respiratory compromise, hypotension, altered mental status, chest pain, or persistent high fever. Documentation should connect symptom onset to the drug, timing, interventions, response, and education provided before discharge.
Practice Priorities
Immune-related toxicity is easy to miss when symptoms resemble common illnesses. Diarrhea may be described as food poisoning, cough as seasonal allergies, fatigue as aging, and headache as stress. The nurse should connect these reports back to the treatment history and ask what changed from baseline. A patient who visited urgent care, received antibiotics, or started steroids elsewhere needs oncology follow-up because outside clinicians may not know the immunotherapy risk. Clear handoffs help prevent fragmented care, duplicate workups, and delayed treatment of serious organ inflammation.
- Ask about symptoms by organ system, not only general side effects.
- Treat new respiratory symptoms during immunotherapy as important until evaluated.
- Reinforce that delayed toxicity can occur after the last dose.
- Confirm the patient knows the oncology contact pathway.
Which patient report during checkpoint inhibitor therapy requires prompt escalation?
What teaching point is most important for a patient receiving immune checkpoint inhibitor therapy?
A nurse notes rising liver function tests in a patient receiving immunotherapy. What is the best RN response?